Ocugen posts clinical presentation showing 84% reduction in mean total atrophy area in treated group

Ocugen, Inc.

Presentation reports mean change in total atrophy area from baseline: 0.12±0.36 mm² (treated) vs 0.73±0.26 mm² (untreated), an 84% difference.
A 44% efficacy metric also cited; specific endpoint not fully legible from exhibit.
Presentation posted on website and may be used in investor discussions; no formal press release or guidance provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.